Cytori Therapeutics to Voluntarily Delist From the Frankfurt Stock Exchange to Consolidate Trading on the NASDAQ Global Market
"This is an opportunity to consolidate trading on one of the most efficient international stock markets, the NASDAQ Global Market, where the vast majority of our shares now trade, while simultaneously reducing redundant fees and expenses associated with a dual listing," said Mark Saad, Chief Financial Officer for Cytori. "All our shareholders will be optimally supported by the single listing and the European investment community will continue to be a priority for us, given our global reach as a regenerative medicine company."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.